Friday, May 30, 2025, Chicago, Illinois, 6:30 PM – 8:30 PM Central Time (7:30 PM – 9:30 PM Eastern Time)

Consensus or Controversy? Clinical Investigators Provide Perspectives on the Current and Future Clinical Care of Patients with EGFR Mutation-Positive Non-Small Cell Lung Cancer

A CME Symposium Held in Conjunction with the 2025 ASCO® Annual Meeting

Register for in-person Register for webcast

Location
Hilton Chicago
720 South Michigan Avenue
Chicago, Illinois
Phone: (312) 922-4400

Program Schedule — Central Time
6:00 PM – 6:30 PM — Registration and Dinner
6:30 PM – 8:30 PM — Educational Meeting

Meeting Room
Continental Room A&B (Lobby Level)

There is no registration fee for this event. For the in-person symposium in Chicago, preregistration is required as seating is limited.  
 
Faculty
Nicolas Girard, MD, PhD
Head of Medical Oncology, Institut Curie
Full Professor
UVSQ, Paris-Saclay University
Paris, France

Jonathan Goldman, MD
Professor of Medicine
UCLA Hematology and Oncology
Director of Clinical Trials in Thoracic Oncology
Associate Director of Drug Development
UCLA Health
Santa Monica, California

Pasi A Jänne, MD, PhD, FASCO
Senior Vice President for Translational Medicine
Lowe Center for Thoracic Oncology
Professor of Medicine
Harvard Medical School
David M Livingston, MD, Chair
Director, Robert and Renée Belfer Center for Applied Cancer Science
Director, Chen-Huang Center for EGFR-Mutant Lung Cancers
Dana-Farber Cancer Institute
Boston, Massachusetts


Suresh S Ramalingam, MD
Executive Director, Winship Cancer Institute
Roberto C Goizueta Chair for Cancer Research
Emory University School of Medicine
Atlanta, Georgia

Joshua K Sabari, MD
Attending Physician
Thoracic Medical Oncology
Assistant Professor of Medicine
NYU Langone Health
Perlmutter Cancer Center
New York, New York

Moderator
Helena Yu, MD
Medical Oncologist
Associate Attending
Memorial Sloan Kettering Cancer Center
New York, New York



This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Johnson & Johnson, and Taiho Oncology Inc.
Program Schedule — Central Time
6:00 PM – 6:30 PM — Registration and Dinner
6:30 PM – 8:30 PM — Educational Meeting

Topics to Be Discussed

  • MODULE 1: Evolving First-Line Treatment for Metastatic EGFR Mutation-Positive Non-Small Cell Lung Cancer (NSCLC) — Dr Yu
  • MODULE 2: EGFR-Targeted Approaches for Relapsed EGFR-Mutant NSCLC; Strategies to Facilitate Delivery of Recently Approved Agents — Dr Sabari
  • MODULE 3: Potential Utility of TROP2-Targeted Therapy in the Management of EGFR-Mutant NSCLC — Dr Ramalingam
  • MODULE 4: Contemporary Care for Patients with Nonmetastatic EGFR-Mutant NSCLC — Dr Goldman
  • MODULE 5: Current and Future Management of EGFR Exon 20 Mutation-Positive NSCLC — Prof Girard
  • MODULE 6: Emerging Role of HER3-Targeted Therapy in the Management of EGFR-Mutant NSCLC — Dr Jänne

Target Audience
This activity is intended for medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of lung cancer.

Learning Objectives
Upon completion of this activity, participants should be able to

  • Acknowledge available clinical trial findings with EGFR tyrosine kinase inhibitors for nonmetastatic EGFR mutation-positive non-small cell lung cancer (NSCLC), and identify patients for whom treatment with this novel approach would be warranted.
  • Counsel patients with newly diagnosed metastatic EGFR mutation-positive NSCLC regarding available therapies, explaining the relevance of mutation type, symptomatology, sites and extent of metastases, prior therapeutic exposure and other factors.
  • Appreciate the biological rationale for dual inhibition of MET and EGFR in patients with EGFR mutation-positive NSCLC, and understand recently presented data establishing the benefit of this strategy.
  • Evaluate the documented efficacy of chemotherapy combined with EGFR-targeted therapy for patients with EGFR mutation-positive metastatic NSCLC, and consider the current role of available approaches in both the front-line and relapsed/refractory settings.
  • Consider the scientific justification for targeting HER3 in patients with EGFR mutation-positive NSCLC, and review the structural components, mechanism of action and available research with novel HER3-directed antibody-drug conjugates (ADCs).
  • Review published research findings with TROP2-directed ADCs for EGFR mutation-positive metastatic NSCLC, and consider the potential clinical role of this strategy.
  • Understand the biology of EGFR exon 20 insertion mutations, and evaluate how currently available therapies should be used in the care of patients with these alterations.
  • Recall the biological rationale for and the design of ongoing clinical trials evaluating novel therapeutic approaches for patients with EGFR mutation-positive NSCLC.

CME Credit Form
A CME credit link will be given to each participant as part of the meeting course materials.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 2 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Privacy Policy
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

Unlabeled/Unapproved Uses Notice
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the provider or grantors.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

Prof Girard — Advisory Committees: AbbVie Inc, Amgen Inc, AstraZeneca Pharmaceuticals LP, Baxter International Inc, Bristol Myers Squibb, Daiichi Sankyo Inc, Gilead Sciences Inc, Janssen Biotech Inc, LEO Pharma, Lilly, MSD, Pfizer Inc, Pierre Fabre, Sanofi, Suven Pharma, Takeda Pharmaceutical Company Limited; Contracted Research (Through Institution): AstraZeneca Pharmaceuticals LP, MSD; Data and Safety Monitoring Boards/Committees: Roche Laboratories Inc; Speakers Bureaus: AbbVie Inc, Amgen Inc, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Daiichi Sankyo Inc, Janssen Biotech Inc, MSD, Sanofi; Nonrelevant Financial Relationships: Clinical Care Options, PeerVoice. Dr Goldman — Consulting Agreements: AbbVie Inc, Amgen Inc, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Genentech, a member of the Roche Group, Janssen Biotech Inc, Lilly, Pfizer Inc, Summit Therapeutics; Contracted Research: AbbVie Inc, Agenus Inc, Amgen Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Genentech, a member of the Roche Group, GSK, Janssen Biotech Inc, Lilly, Merck, Pfizer Inc, Puma Biotechnology Inc, RayzeBio Inc, Summit Therapeutics, Tango Therapeutics. Dr Jänne — Advisory Committees: AbbVie Inc, Accutar Biotechnology Inc, Allorion Therapeutics, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biocartis, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Chugai Pharmaceutical Co Ltd, Daiichi Sankyo Inc, Dizal Pharma, Duality Biologics, Eisai Inc, Frontier Medicines, Genentech, a member of the Roche Group, GSK, Hongyun Biotechnology, Lilly, Merus, Mirati Therapeutics Inc, Monte Rosa Therapeutics, Myris Therapeutics, Novartis, Nuvalent, Pfizer Inc, Roivant, Sanofi, Scorpion Therapeutics, SFJ Pharmaceuticals, Syndax Pharmaceuticals, Takeda Pharmaceuticals USA Inc, TOLREMO, Transcenta, Voronoi; Contracted Research (All to Institution): AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, Daiichi Sankyo Inc, Lilly, Puma Biotechnology Inc, Revolution Medicines, Takeda Pharmaceuticals USA Inc; Royalties: Postmarketing royalties from Dana-Farber Cancer Institute-owned intellectual property on EGFR mutations licensed to Labcorp; Stock Options — Private Company: Frontier Medicines. Dr Ramalingam — Contracted Research (Research Support to Institution): Amgen Inc, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, Merck, Pfizer Inc; Data and Safety Monitoring Boards/Committees: Gilead Sciences Inc, Johnson & Johnson Pharmaceuticals (no honorarium received). Dr Sabari — Advisory Committees and Consulting Agreements (Advisory Boards/Consultant, Personal Fees): AbbVie Inc, AstraZeneca Pharmaceuticals LP, Bristol Myers Squibb, EMD Serono Inc, Genentech, a member of the Roche Group, Janssen Biotech Inc, Jazz Pharmaceuticals Inc, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Mirati Therapeutics Inc, Pfizer Inc, Regeneron Pharmaceuticals Inc, Revolution Medicines, Sanofi, Takeda Pharmaceuticals USA Inc; Contracted Research (Institutional): Bristol Myers Squibb, Janssen Biotech Inc, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Mirati Therapeutics Inc, Regeneron Pharmaceuticals Inc.

MODERATOR — Dr Yu — Consulting Agreements: AbbVie Inc, Amgen Inc, AstraZeneca Pharmaceuticals LP, Black Diamond Therapeutics Inc, Bristol Myers Squibb, Cullinan Therapeutics, Daiichi Sankyo Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, Pfizer Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc; Contracted Research (To Institution): AstraZeneca Pharmaceuticals LP, Black Diamond Therapeutics Inc, Cullinan Therapeutics, Daiichi Sankyo Inc, Janssen Biotech Inc, Kumquat Biosciences, SystImmune Inc, Taiho Oncology Inc; Data and Safety Monitoring Boards/Committees: Janssen Biotech Inc, Mythic Therapeutics.

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS
Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

Supporters
This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Johnson & Johnson, and Taiho Oncology Inc.

Hilton Chicago
720 South Michigan Avenue
Chicago, IL 60605
Phone: (312) 922-4400

Meeting Room
Continental Room A&B (Lobby Level)

Directions
The Hilton Chicago hotel is located just 5 minutes (2.5 miles) north of the McCormick Place convention center, where the ASCO Annual Meeting is taking place.

 
This activity is intended for medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of lung cancer.

There is no registration fee for this event. For the in-person symposium in Chicago, preregistration is required as seating is limited.

NOTICE:
Registration for this event is independent of registration for the 2025 ASCO® Annual Meeting.

IN-PERSON Registration for clinicians in practice/healthcare professionals

I am a practicing physician, fellow, nurse or other healthcare provider involved in the treatment of cancer.

IN-PERSON Registration
for clinicians »
IN-PERSON Registration for other/industry professionals*

Please note, a limited number of seats are available to other/industry professionals on a first come, first served basis.

IN-PERSON Registration
for nonclinicians »
 
* Individuals employed by for-profit organizations, including financial institutions, biotech or pharmaceutical companies
WEBCAST Registration for all professionals

Please note, we will stream this event over Zoom. After registering you will receive a separate confirmation from Zoom with the viewing instructions.

REGISTRATION FOR WEBCAST »
Registration for groups
If you are registering a group (more than 1 person) for this event, please contact us at Meetings@ResearchToPractice.com or (800) 233-6153.
To ensure seating and meal service, please check in at our onsite registration desk before the start of the meeting. We cannot guarantee seating after the start of the program.

Photography and/or video recording may be taken during the educational program by Research To Practice and used in future educational offerings.

Research To Practice fully complies with the legal requirements of the ADA. If you require any physical, dietary or other accommodations, please call us at (800) 233-6153 before the event.

Not an official event of the 2025 ASCO® Annual Meeting. Not sponsored, endorsed, or accredited by ASCO®, Association for Clinical Oncology, or Conquer Cancer®, the ASCO Foundation.